MG
RBOT

Michael Gelband’s Vicarious Surgical RBOT Stock Holding History

Michael Gelband’s Portfolio RBOT Stock Details RBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-4,069
Closed -$618K – 2356
2022
Q1 		$618K Buy
+4,069
New +$757K 0.01% 1412

Other funds holding RBOT

VS
VK Services Menlo Park, California $1.01M AUM 157.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AMH
Aspex Management (HK) Central, Hong Kong $8.89B AUM 39.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
HVCM
Hel Ved Capital Management Central, Hong Kong $1.36B AUM 336.43% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
DP
DDD Partners Bellevue, Washington $1.6B AUM 17.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Michael Gelband's RBOT Position: Q2 2022 in Review

Michael Gelband sold out of Vicarious Surgical (RBOT) in Q2 2022, closing a stake of 4,069 shares — an estimated $618K sold.

Michael Gelband first reported a position in RBOT in Q1 2022 and held it in 1 quarter. The position peaked at $618K in Q1 2022. 79 funds tracked by Wall St. Rank hold RBOT as of Q2 2022.

  • Michael Gelband reported no remaining Vicarious Surgical position as of Q2 2022 after selling out during the quarter.
  • Michael Gelband sold 4,069 Vicarious Surgical shares in Q2 2022, an estimated $618K.
  • Michael Gelband first reported a position in Vicarious Surgical in Q1 2022 and held it in 1 quarter.
  • Michael Gelband's Vicarious Surgical position peaked at $618K in Q1 2022.
  • 79 funds tracked by Wall St. Rank held Vicarious Surgical as of Q2 2022.

Based on ExodusPoint Capital Management's 13F filing for Q2 2022, filed 22 Aug 2022.